Biogen Inc. Class Action Lawsuit - BIIB

(1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer’s disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

In order to be eligible to join the BIIB class action lawsuit, you must have incurred a loss on shares of Biogen purchased during the class period listed above.

If you suffered a loss in Biogen during the relevant time frame or pursuant to the relevant offering(s), you have until January 12, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.